The company has until October 30, 2026 to file an appeal, which would stay the delisting pending a hearing panel decision. The company claims it has already cured the deficiency after the notice date, but the panel's decision is uncertain. Monitor for the appeal filing and any subsequent Nasdaq determination.
Price Chart
Executive Summary
Propanc Biopharma received a delisting notice from Nasdaq on October 23, 2026, for failing to meet the $1.00 minimum bid price requirement. Because the company had already executed a reverse stock split within the prior year, it is not eligible for the standard 180-day cure period. Nasdaq has scheduled delisting for November 2, 2026, unless the company appeals by October 30, 2026; the company intends to appeal and believes it has already cured the deficiency.
Key Facts
- Received delisting notice from Nasdaq on October 23, 2026 for non-compliance with minimum bid price rule 5550(a)(2)
- Closing bid price was below $1.00 for 30 consecutive business days prior to October 21, 2026
- Not eligible for 180-day compliance period due to a reverse stock split within the prior year (Rule 5810(c)(3)(A)(iv))
- Delisting scheduled for November 2, 2026 unless appeal is requested by October 30, 2026
- Company intends to appeal by the deadline and believes it has already cured the bid price deficiency
- Market cap is $3M with a normal daily move of 6.6%
Financial Impact
Potential delisting from Nasdaq Capital Market, which would severely reduce liquidity, institutional ownership, and access to public capital markets for a $3M market cap company
Risk Factors
- If appeal is denied or not filed, delisting will occur on November 2, 2026
- Delisting would severely reduce liquidity and market price of common stock
- Delisting would impair ability to raise equity financing and access public capital markets
- Inability to use registration statements for freely tradable securities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-049298 |
| Document: 0001493152-26-049298-index-headers.html | 0001493152-26-049298 |
| Document: 0001493152-26-049298-index.html | 0001493152-26-049298 |
| Document: 0001493152-26-049298.txt | 0001493152-26-049298 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | Press Release | $2.10 | awaiting T+5 | awaiting T+5 | $1.84 (−12.38%) |
Oct 29, 2026 3d ago | 8-K | $2.14 | awaiting T+5 | awaiting T+5 | $1.84 (+14.02%) |
Oct 28, 2026 4d ago | Press Release | $2.11 | awaiting T+5 | awaiting T+5 | $1.84 (−12.80%) |
Oct 22, 2026 10d ago | Press Release | $0.2800 $0.1840 | ▼ −34.29% | ▼ −33.73% | $1.84 (+557.14%) |
Oct 5, 2026 26d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $1.84 (−274.52%) |
Sep 29, 2026 4w ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $1.84 (+259.16%) |
Aug 18, 2026 10w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $1.84 (+58.62%) |
Jul 14, 2026 15w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $1.84 (+12.88%) |
May 19, 2026 23w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $1.84 (−8.23%) |
May 15, 2026 24w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $1.84 (+8.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers